Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Chin Clin Oncol ; 9(5): 70, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32954737

RESUMEN

The treatment of ovarian cancer should be appropriate, since clinical and surgical decisions may affect the prognosis; the surgery must be performed by an expert oncological surgeon or gynecological oncologist, it's fundamental roles are cancer staging and cytoreduction. The concept of staging surgery in early stages has its justification in the fact that up to 11% of "early ovarian cancers" will have metastasis in different sites of the peritoneal cavity at the time of diagnosis. In advanced stages of epithelial ovarian cancer, the goal is the complete cytoreduction of all visible macroscopic disease, since this variable is the most strongly associated with increased overall survival and disease-free period. The ideal time for cytoreductive surgery in relation to chemotherapy (before or after) is still under debate. In 2010 a randomized trial (EORTC) was published, comparing 310 patients initially operated (followed by adjuvant chemotherapy) versus 322 patients initially treated with neoadjuvant chemotherapy (followed by cytoreductive surgery); no significant differences in overall survival between groups were found. Another important factor playing a role in survival and in the probability of surgical cytoreductive success is tumor biology; there has been described a clear difference between serous and mucinous tumors, but some groups advocate that maximal surgical effort in mucinous tumors may compensate morbidity with an increase in survival. The extension of resection in cytoreduction is still controversial; some authors have confirmed that the most important factor is the residual disease and that radical surgery is superior to non-radical surgery in terms of overall survival. The need and extent of lymphadenectomy in advanced cancer will be treated in another chapter of this issue. Undoubtedly, an important factor is to perform procedures in specialized centers.


Asunto(s)
Procedimientos Quirúrgicos de Citorreducción/métodos , Neoplasias Ováricas/cirugía , Femenino , Humanos
2.
Biomed Res Int ; 2020: 2196024, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32733932

RESUMEN

Endometriosis is one of the most frequent gynecological diseases in reproductive age women, but its etiology is not completely understood. Endometriosis is characterized by progesterone resistance, which has been explained in part by a decrease in the expression of the intracellular progesterone receptor in the ectopic endometrium. Progesterone action is also mediated by nongenomic mechanisms via membrane progesterone receptors (mPRs) that belong to the class II members of the progesterone and adipoQ receptor (PAQR) family. The aim of the present study was to evaluate the expression at mRNA and protein levels of mPR members in the eutopic and ectopic endometrium of women with endometriosis. Total RNA and total protein were isolated from control endometrium (17 samples), eutopic endometrium (17 samples), and ectopic endometrium (9 samples). The expression of PAQR7 (mPRα), PAQR8 (mPRß), and PAQR6 (mPRδ) at mRNA and protein levels was evaluated by RT-qPCR and Western blot, whereas PAQR5 (mPRγ) gene expression was evaluated by RT-qPCR. Statistical analysis between comparable groups was performed using one-way ANOVA followed by Tukey's multiple comparisons test with a confidence interval of 95 %. The analysis of gene expression showed that PAQR7 and PAQR5 expression was lower in both eutopic and ectopic endometrium as compared to the endometrium of women without endometriosis, whereas the expression of PAQR8 and PAQR6 was only reduced in eutopic endometrium. Furthermore, mPRα and mPRß protein content was decreased in the ectopic endometrium of women with endometriosis. Our results demonstrate a decrease in the expression and protein content of mPRs in eutopic and ectopic endometrium of patients with endometriosis, which could contribute to the progesterone resistance observed in patients with this disease.


Asunto(s)
Membrana Celular/metabolismo , Endometriosis/metabolismo , Endometrio/metabolismo , Receptores de Progesterona/metabolismo , Adulto , Regulación hacia Abajo/genética , Endometriosis/patología , Endometrio/patología , Femenino , Humanos , Proteínas de la Membrana/genética , Proteínas de la Membrana/metabolismo
3.
Ginecol Obstet Mex ; 78(10): 540-6, 2010 Oct.
Artículo en Español | MEDLINE | ID: mdl-21966771

RESUMEN

BACKGROUND: The discomfort of vaginal infection symptoms is a frequent cause of medical consultation. OBJECTIVE: To determine the degree of satisfaction reported by a group of Mexican patients used the combination lactoserum lactic acid and to the relief of vulvovaginal symptoms (odor, itching and burning) or not associated with infection and the safety of that combination when used for external genital hygiene daily. PATIENTS AND METHOD: Clinical observational, prospective, multicenter open and made with a group of Mexican women 18-60 years of age, residents in cities across the country with some or vulvovaginal symptoms: foul odor, itching, burning. All participants were told the application, once daily, 2.5 to 5 mL of shampoo, for 14-21 days. The patients rated the presence and severity of vulvar discomfort with visual analogue scale. The data were analyzed with Statistical Analysis System statistical package version 9.1, the quantitative variables by calculating the mean +/- standard deviation, categorical variables by calculating percentages. RESULTS: We included 559 patients who answered the questionnaires before and after treatment. The time-use shampoo study was variable, with less than seven days were 25 patients (4.5%), 8 to 14 days 123 patients (22.0%) of 15 to 21 days, 208 patients (37.3%) and 178 patients (31.9%) used it more than 21 days. The average time elapsed since the start of treatment until the disappearance of vulvar discomfort was 4.3 days, with a SD of 3.1. In symptomatic patients the average was 4.2 days (SD 3.3), while in asymptomatic patients was 4.4 days (SD 3.0), virtually the same between groups. At the time of the final visit, 92.2% of patients reported "feeling of cleanliness" in the genital area, 91.7% "fresh feeling" and 93.9% "general feeling of wellbeing". 97.2% felt that the product is "user friendly", 94.9% considered it "soft and gentle to the skin" and 95.2% described it with "pleasing aroma". CONCLUSIONS: Shampoo daily female external genital hygiene, the reason for this study is useful in the disappearance of the symptoms associated with infection or vulvovaginal.


Asunto(s)
Sueros Inmunes/administración & dosificación , Inmunización Pasiva , Ácido Láctico/uso terapéutico , Vulvovaginitis/terapia , Adolescente , Adulto , Enfermedades Asintomáticas , Terapia Combinada , Femenino , Productos para la Higiene Femenina , Humanos , Ácido Láctico/administración & dosificación , Persona de Mediana Edad , Satisfacción del Paciente , Estudios Prospectivos , Prurito/tratamiento farmacológico , Prurito/terapia , Encuestas y Cuestionarios , Vulvovaginitis/tratamiento farmacológico , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...